On April 1, 2026, the statutory health insurance (GKV) lung cancer screening program will launch – a significant step toward early diagnosis and improved care for at-risk patients. With reimbursement guidelines now finalized and eight new billable services, the groundwork has been laid for widespread implementation.
The 107th German Radiology Congress (RÖKO), taking place May 13–15, 2026, in Leipzig, Germany, offers the ideal opportunity to learn about suitable solutions.
At MeVis, we provide radiologists with optimal support: With our Veolity portfolio, we offer flexible and powerful solutions for the interpretation of chest CTs in the context of lung cancer screening – tailored to different requirements and workflows:
Veolity Lung CAD1
AI-based round lesion detection and quantification, including follow-up monitoring – seamlessly integrated into your existing PACS workflow.
Veolity LungRead
The efficient reporting solution: from AI-assisted analysis to a structured, guideline-compliant report.
Veolity One2
The comprehensive platform: a centralized, cloud-based solution for all medical and organizational screening processes—including the integration of all stakeholders, from the referring physician through initial to secondary interpretation.
Visit us on-site at booth no. C25 in hall 2 and discover how we can support you in launching your screening program. We look forward to connecting with you!
1Veolity LungCAD is a licensable configuration of Veolity.
2Veolity ONE is a bundle of different software applications, including third-party software.